Efficacy and safety of modified PAD regimen in the treatment of primary multiple myeloma
10.12025/j.issn.1008-6358.2016.20160518
- VernacularTitle:改良 PAD方案治疗初发多发性骨髓瘤的疗效及安全性
- Author:
Jian ZOU
1
;
Li-Hua SUN
;
Ya-Hong MENG
;
Xiao-Hong FAN
;
Xue-Lian WANG
Author Information
1. 复旦大学附属中山医院青浦分院血液科
- Keywords:
multiple myeloma;
bortezomib;
efficacy;
safety
- From:
Chinese Journal of Clinical Medicine
2016;23(6):782-784
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of two PAD regimens with different doses of bortezomib (bortezomib + Epirubicin + dexamethasone) in the treatment of patients with multiple myeloma (MM ) .Methods :The clinical data of 32 MM patients treated with PAD regimens were retrospectively analyzed .The doses of intravenous bortezomib were different in two PAD regimens .Patients in group PAD 1 (n=20) received bortezomib 1 .3 mg/m2 through intravenous injection on d 1 ,d 4 ,d 8 ,and d 11 ,epirubicin 20 mg through intravenous infusion on d 1 to d 4 ,and dexamethasone 20 mg through intravenous infusion d 1 to d 4 ,and d 8 to d 11 .Patients in group PAD 2 (n=12) received bortezomib 1 .6 mg/m2 through intravenous injection on d 1 ,d 8 ,and d 15 ,epirubicin 20 mg through intravenous infusion on d 1 ,d 8 ,and d 15 ,and dexamethasone 20 mg through intravenous infusion on d 1‐2 ,d 8‐9 ,and d 15‐16 .All patients received 3 to 6 courses of treatment and each course lasted for 28 days .Clinical efficacy and adverse reactions of two groups of MM patients were compared after the completion of 3 courses .Results:After the first three courses ,the effective rate of group PAD 1 was 80 .0% ,the effective rate of group PAD 2 was 83 .3% ,and there was no significant difference between the two groups .There were more herpes zoster patients in group PAD 1 than group PAD 2 (30% vs 0% ) ,and the difference was statistically significant (P<0 .05) .There were no statistical differences in the incidence of gastrointestinal reaction ,peripheral neuritis , granulocytopenia ,and thrombocytopenia between the two groups (20 .0% vs 16 .7% ,25 .0% vs 16 .7% ,15 .0% vs 16 .0% , and 10 .0% vs 8 .0% ,P>0 .05) .Conclusions :The PAD regimen with intravenous injection of bortezomib 1 .6 mg/m2 once a week is similar to the PAD regimen with intravenous injection of bortezomib 1 .3 mg/m2 twice a week in efficacy ,but it is safer with less adverse reactions .
